https://www.selleckchem.com/pr....oducts/epz004777.htm
f detected lesions. The false-negative rate was 35% (14.2% [two of 14] of patients had CSCs; GS ≥ 7), was higher in prostate volumes of greater than 40 mL, and was lower in the anterior gland location ( = .04 and .01, respectively). Performing confirmatory in-bore MRI-guided biopsy following positive transrectal US-guided biopsy resulted in a high disease-upgrade incidence with subsequently improved disease-risk stratification, particularly when considering patients for active surveillance or focal therapy. © RSNA, 2020See also the co
Curtir
Comentario
Compartilhar
